Credit Limit Enhancement Deacon at a Pharmaceutical Major
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : FINC088
Case Length : 9 pages
Period :
Pub. Date : 2013
Teaching Note : Available
Organization :Remedy Laboratories Limited
Industry : Pharmaceutical
Countries : India
To download Credit Limit Enhancement Deacon at a Pharmaceutical Major case study (Case Code:
FINC088) click on the button below, and select the case from the list of available cases:
OR
Price:
For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs. 300 + Rs. 25 for Shipping &
Handling Charges
» Finance Case
Studies
» Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
|
<< Previous
Excerpts
Africa: The Rising Opportunity
|
By 2016, the African pharmaceutical sector was expected to reach US $30 billion . The expected CAGR was around 10.6% through 2016, which was the second fastest growth rate after the Asia Pacific region. Various factors like increase in wealth, investments in health, and the rise in the demand for drugs for treating chronic diseases stimulated by the convergence of democratic changes contributed to the growth. It was felt that the market could also reach US$45 billion by 2020 . According to the Economist Intelligence unit, the economies of Sub-Saharan Africa (SSA), excluding South Africa, had been the fastest growing economies in the world...
|
|
Taking a Dicision
Surimex Pharmaceuticals (SP), a France-based distributor, was a major distributor of RLL in Africa with a presence in French speaking Africa and France. It distributed RLL products in West and Central African countries. RLL saw West Africa as a great export opportunity and wanted to increase its penetration and market presence in that market. This increase in market presence was not possible without a strong relationship with distributors like SP.
SP was founded in 1994. It specialized in pharmaceutical distribution and filing and storage of pharmaceutical chemicals and products. It offered its services to pharmaceutical companies and took care of their logistics and distribution in francophone Africa, overseas territories, and in France. SP was a private SAS (simplified joint stock company) with a paid up capital of €160,000. It had bonded warehouse status and pharmaceutical establishments in depository activities and was a wholesale export distributor. It did not belong to any subsidiary of international laboratories or buying offices. This enabled it to sell its products in all types of markets, public or private....
...
Exhibits
Exhibit I: D&B Report
Exhibit II: Existing Terms between RLL and SP and Sales Turnover
Exhibit III:Key Financial Ratios of SP
Exhibit IV: Financial Comparison of SP
Exhibit V: Balance Sheet of SP
Exhibit VI: Profit & Loss account of SP
Exhibit VII: Sales Turnover & Past Payments Record SP
Excerpts
- Next Page>>
|
|
